13 النتائج
BACKGROUND OF THE INVENTION
The cystic fibrosis transmembrane conductance regulator protein (CFTR) is a cAMP-activated chloride (Cl.sup.-) channel expressed in epithelial cells in mammalian airways, intestine, pancreas and testis. CFTR is the chloride-channel responsible for cAMP-mediated Cl.sup.-
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to methods and formulations for the therapy of cystic fibrosis, Bartter's syndrome and secretory diarrheas such as cholera, and for diuretic treatment.
2. Discussion of the Background
Cystic fibrosis: This is a
BACKGROUND
1. Field
Agents are needed for treating diseases and disorders related to aberrant cystic fibrosis transmembrane conductance regulator protein (CFTR) such as increased intestinal fluid secretion, secretory diarrhea, and polycystic kidney disease. Small molecule conjugates are described
BACKGROUND OF THE INVENTION
The present understanding of the underlying pathophysiological mechanism of acute secretory diarrhea is growing steadily. Secretory diarrhea can accompany gastrointestinal disorders such as inflammatory bowel disease. Acute diarrhea is a world-wide problem, and easily
TECHNICAL FIELD
The present invention relates to ion channel activating agents. More particularly, the present invention relates to a particular class of chemical compounds that has proven useful as openers of SK.sub.Ca and IK.sub.Ca channels. In further aspects, the present invention relates to the
The present invention relates to novel adenosine A.sub.2B receptor, agonists, pharmaceutical compositions containing them, and to methods of treating conditions and diseases mediated by the adenosine A.sub.2B receptor activity, by employing such compounds.
Accordingly, the present invention provides
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates generally to compounds and methods for modulating chloride ion transport, and, more specifically, to antagonists and agonists of inositol polyphosphates.
2. Background Information
All living organisms are made of
BACKGROUND OF THE PRESENT INVENTION
1. Field of Invention
The subject invention relates generally to a series of natural pharmaceutical preparations which can treat hypoproteinemia for increasing albumin. The preparations could be used to treat hypoproteinemia caused by hepatitis virus, human
TECHNICAL FIELD
The present invention relates generally to nutrition and more particularly to a method of use and nutritional compositions containing .alpha.-glucosidase inhibitors, and more specifically Touchi Extract.
BACKGROUND OF THE INVENTION
Touchi Extract (TE) is a water-extract powder of
FIELD OF THE INVENTION
This application and invention disclose hydrazone-containing compounds that inhibit the transport of ions (e.g., chloride ions) across cell membranes expressing the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The structures of these CFTR inhibitory
FIELD OF THE INVENTION
This application and invention disclose oxadiazole-containing compounds that inhibit the transport of ions (e.g., chloride ions) across cell membranes expressing the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The structures of these CFTR inhibitory
BACKGROUND OF THE INVENTION
The present invention is directed to cyclic peptides that have somatostatin agonist activity, as defined by formula (I), shown and defined hereinbelow, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising said peptides and the use thereof
BACKGROUND OF THE INVENTION
The present invention is directed to cyclic peptides that have somatostatin agonist activity, as defined by formula (I), shown and defined hereinbelow, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising said peptides and the use thereof